Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
---|
01/29/1998 | WO1997036609A3 Combinations of vasopressin and adrenergic agents for the treatment of cardiac arrest |
01/29/1998 | DE3745019C2 Cross-protective human monoclonal antibody compsns. |
01/29/1998 | DE19632755C1 Monoclonal antibody specific for CDw109 cell surface protein |
01/29/1998 | DE19630557A1 Gewebe-Transglutaminase (EC 2.3.13, tTG), in der Eigenschaft als Autoantigen der einheimischen Sprue/Zöliakie, welches spezifisch durch Antikörper aus Seren von Patienten mit einheimischer Sprue erkannt wird; Tissue transglutaminase (EC 2.3.13, tTG), in its capacity as autoantigen of celiac local / celiac disease, which is specifically recognized by antibodies from sera of patients with endemic sprue; deren Verwendung in Diagnostik, Therapiekontrolle und Therapie der Sprue, sowie anderer Erkrankungen/Symptome, die mit einer Immunreaktion gegen die tTG einhergehen their use in diagnosis, therapy monitoring and treatment of celiac disease, and other diseases / symptoms associated with an immune reaction against tTG |
01/29/1998 | DE19630390A1 Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung Proteins, especially membrane proteins from Helicobacter pylori, their preparation and use |
01/29/1998 | CA2262863A1 Antiviral linear polymers |
01/29/1998 | CA2262008A1 Bivalent agonists for g-protein coupled receptors |
01/29/1998 | CA2261898A1 Diagnostic and therapeutic nucleotide or nucleoside photoaffinity compound modified antibodies, and use thereof |
01/29/1998 | CA2261885A1 Substance p treatment for immunostimulation |
01/29/1998 | CA2261797A1 Cyclic peptides having broad spectrum antimicrobial activity |
01/29/1998 | CA2261570A1 Use of conantokins |
01/29/1998 | CA2261568A1 Conantokins |
01/29/1998 | CA2261013A1 Human kallikrein |
01/29/1998 | CA2260767A1 Fas ligand-like protein, its production and use |
01/29/1998 | CA2260763A1 Melatonin 1a receptor gene regulatory regions and uses thereof |
01/29/1998 | CA2260752A1 Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways |
01/29/1998 | CA2236036A1 Signal-regulated, cleavage-mediated toxins |
01/29/1998 | CA2232142A1 Cd6 ligand |
01/28/1998 | EP0821066A1 Polypeptide of glycosaminoglycan sulfotransferase originating from human and DNA coding for the polypeptide |
01/28/1998 | EP0821061A2 Calcitonin gene-related peptide receptor component factor (houdc44) |
01/28/1998 | EP0821060A2 Diagnosis and therapy of human malign tumors based on E-cadherin mutations |
01/28/1998 | EP0821007A2 Aprotinin variants with improved properties |
01/28/1998 | EP0821006A2 Derivatives of insulin having enhanced zinc binding activity |
01/28/1998 | EP0821004A1 Novel peptides and remedy for bone diseases containing the same as active ingredient |
01/28/1998 | EP0821003A1 Peptides and remedy for autoimmune diseases comprising the same |
01/28/1998 | EP0820773A1 Treatment of diabetes with a glucokinase gene |
01/28/1998 | EP0820515A1 Phospholipase c homolog |
01/28/1998 | EP0820512A1 New chemokine expressed in eosinophils |
01/28/1998 | EP0820511A1 Probe for the early detection of displasias in multilayer tesselated epithelium and for the diagnosis and therapy of carcinomas |
01/28/1998 | EP0820510A1 Cancer diagnosis and therapy based on mutations in tgf-beta receptors |
01/28/1998 | EP0820508A1 Dumbbell sense oligonucleotide for inhibiting herpes simplex virus (hsv) |
01/28/1998 | EP0820507A1 Ndf peptides |
01/28/1998 | EP0820472A1 Monoclonal antiidiotypic antibodies (ab2) and uses thereof |
01/28/1998 | EP0820470A1 Novel anti-aids immunotoxins |
01/28/1998 | EP0820469A1 Identification, purification and uses of leczymes and carbohydrate ligands |
01/28/1998 | EP0820467A1 Methods of treating disorders of the eye |
01/28/1998 | EP0820464A2 Cysteine protease inhibitor |
01/28/1998 | EP0820453A1 Thrombin inhibitors |
01/28/1998 | EP0820433A1 O-malonyltyrosyl compounds, o-malonyltyrosyl compound-containing peptides, and uses thereof |
01/28/1998 | EP0820314A1 Autologous fibrin glue and methods for its preparation and use |
01/28/1998 | EP0820311A1 Transplantation of genetically modified cells having low levels of class i mhc proteins on the cell surface |
01/28/1998 | EP0820310A1 Method for in vivo regulation of cardiac muscle contractility |
01/28/1998 | EP0820303A1 PEPTIDE p277 ANALOGS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR TREATMENT OR DIAGNOSIS OF DIABETES |
01/28/1998 | EP0820302A1 Combination compositions containing benazepril or benazeprilat and valsartan |
01/28/1998 | EP0820300A1 Controlled release biodegradable nanoparticles containing insulin |
01/28/1998 | EP0820299A1 Formulations for il-12 |
01/28/1998 | EP0820298A1 Peptide growth factor having epidermal inducing activity |
01/28/1998 | EP0820297A1 Method of using lectins for prevention and treatment of oral and alimentary tract disorders |
01/28/1998 | EP0820296A1 Analogs of growth hormone-releasing factor |
01/28/1998 | EP0820295A1 Modified lysine or arginine containing proteins and peptides |
01/28/1998 | EP0820291A1 A pharmaceutical composition containing n-phosphonoglycine derivatives for inhibiting the growth of viruses and cancers |
01/28/1998 | EP0820290A1 Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism |
01/28/1998 | EP0820285A1 Methods and compositions for lipidization of hydrophilic molecules |
01/28/1998 | EP0820277A1 Powdered pharmaceutical formulations having improved dispersibility |
01/28/1998 | EP0672679B1 Phospholipase c inhibiting peptide |
01/28/1998 | EP0654046B1 Auto-cross-linked gellan gum |
01/28/1998 | EP0422217B1 Human recombinant placental ribonuclease inhibitor and method of production |
01/28/1998 | CN1171822A Hydroxyproline-rich proteins and pharmaceutical and cosmetic formulations containing them |
01/28/1998 | CN1171816A CDNA encoding BMP type II receptor |
01/28/1998 | CN1171815A Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from fusion product in aspergillus |
01/28/1998 | CN1171792A Novel monoclonal antibody having inhibitory effect on type II phospholipase A2 and protein containing part of same |
01/28/1998 | CN1171791A Purified thrombopoietin and method of making it |
01/28/1998 | CN1171743A Novel tumor suppressor gene HIC-1 |
01/28/1998 | CN1171742A Selective acylation of epsilon-amino groups |
01/28/1998 | CN1171268A Mixture containing SOD and VC for supplementing body energy |
01/28/1998 | CN1171267A Clinical application of gamma-interferon in emergency contraception |
01/28/1998 | CN1171248A Chinese medicine capsule for treating apoplexy |
01/28/1998 | CN1037201C 多元溶剂清洗系统 Multiple solvent cleaning system |
01/27/1998 | US5712417 Inhibitors of retroviral proteases |
01/27/1998 | US5712397 Amino acid derivatives, processes for preparing them and pharmaceutical compositions containing these compounds |
01/27/1998 | US5712395 Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
01/27/1998 | US5712384 Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
01/27/1998 | US5712381 MADD, a TNF receptor death domain ligand protein |
01/27/1998 | US5712380 Angiogenesis inhibitor |
01/27/1998 | US5712375 Systematic evolution of ligands by exponential enrichment: tissue selex |
01/27/1998 | US5712373 HIV monoclonal antibody specific for the HTLV-IIImn gp120 envelope glycoprotein |
01/27/1998 | US5712370 Erythropoietin (EPO) peptides and antibodies directed against these |
01/27/1998 | US5712307 Methods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using phemylacetic acids and derivatives therof |
01/27/1998 | US5712291 Methods and compositions for inhibition of angiogenesis |
01/27/1998 | US5712273 Amino acid derivatives, processes for the manufacture thereof and pharmaceutical compositions (II) containing these compounds |
01/27/1998 | US5712265 Administration of pirenzepine, methyl scopolamine and other muscarinin receptor antagonists for treatment of glucose metabolism disorders |
01/27/1998 | US5712252 Keratin injection |
01/27/1998 | US5712251 Treatment method |
01/27/1998 | US5712250 Product for inhibition of human rotavirus infection |
01/27/1998 | US5712249 Use of insulin-like growth factors I and II for inhibition of inflammatory response |
01/27/1998 | US5712247 Use of lactoferrin to modulate and/or neutralize heparin activity |
01/27/1998 | US5712245 Protection against infection |
01/27/1998 | US5712160 From nerve growth factor receptor protein, applications to alzheimers*s disease and parkinson*s disease |
01/27/1998 | US5712159 Glucose responsive insulin secreting β-cell lines and method for producing same |
01/27/1998 | US5712155 DNA encoding tumor necrosis factor-α and -β receptors |
01/27/1998 | US5712149 Chimeric receptor molecules for delivery of co-stimulatory signals |
01/27/1998 | US5712148 Gamma-aminobutyric acid, vectors, plasmids |
01/27/1998 | US5712145 Hepatitis C virus protease |
01/27/1998 | US5712136 Adenoviral-mediated cell targeting commanded by the adenovirus penton base protein |
01/27/1998 | US5712122 Carboxy terminal peptide-extended proteins |
01/27/1998 | US5712121 Treatment of illnesses with demonstrated eosinophilia |
01/27/1998 | US5712120 Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them |
01/27/1998 | US5712118 Vaccine for branhamella catarrhalis |
01/27/1998 | US5712117 Cytoplasmic antiproteinase-2 and coding sequences |
01/27/1998 | US5712115 Polynucleotide encoding polypeptide with amino acid sequences |